Susan List
Psychiatry · Vero Beach, FLNPI 1003323429
Payments from drug & device makers
Across 231 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$837
- Alkermes, Inc.$780
- Otsuka America Pharmaceutical, Inc.$691
- Johnson & Johnson$684
- Neurocrine Biosciences, Inc.$592
- AbbVie$555
- plus $2K from 13 others
What the payments were for
- Food & beverage$6,096100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $837 |
| Alkermes, Inc. | 27 | $780 |
| Otsuka America Pharmaceutical, Inc. | 23 | $691 |
| Johnson & Johnson | 21 | $684 |
| Neurocrine Biosciences, Inc. | 22 | $592 |
| AbbVie | 27 | $555 |
| Axsome Therapeutics, Inc. | 12 | $407 |
| E.r. Squibb & Sons, L.L.C. | 14 | $389 |
| Lundbeck LLC | 18 | $324 |
| Vanda Pharmaceuticals Inc. | 10 | $300 |
| Teva Pharmaceuticals USA, Inc. | 6 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Almatica Pharma LLC | 3 | $78 |
| Noven Therapeutics, LLC | 3 | $60 |
| Eisai Inc. | 1 | $28 |
| Corium, LLC | 1 | $26 |
| Braeburn Inc. | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,101 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 23 | $41,727 |
| Duloxetine Hcl | 40 | $3,626 |
| Bupropion XlBupropion Hcl | 55 | $2,062 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $1,698 |
| Chlorpromazine Hcl | 11 | $1,034 |
| Mirtazapine | 31 | $567 |
| Gabapentin | 40 | $561 |
| Clonazepam | 50 | $560 |
| Lamotrigine | 32 | $536 |
| Buspirone Hcl | 18 | $525 |
| Hydroxyzine Hcl | 17 | $356 |
| Quetiapine Fumarate | 31 | $348 |
| Trazodone Hcl | 51 | $333 |
| Lorazepam | 42 | $323 |
| Prazosin Hcl | 16 | $262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $691 | $41,72723 claims |
| Almatica Pharma LLCSertraline Hcl | $78 | $12429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Vero Beach
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.